Ascent Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-35,484
Closed -$130K – 217
2026
Q2
$130K Buy
35,484
+7,403
+26% +$24.6K 0.01% 199
2026
Q1
$86.2K Buy
28,081
+2,974
+12% +$11.5K 0.01% 187
2025
Q4
$103K Buy
25,107
+3,336
+15% +$16.5K 0.01% 181
2025
Q3
$106K Buy
21,771
+4,275
+24% +$22.5K 0.01% 179
2025
Q2
$88.5K Buy
+17,496
New +$86K 0.01% 171

Other funds holding RXRX

Ascent Wealth Partners's RXRX Position: Q3 2026 in Review

Ascent Wealth Partners sold out of Recursion Pharmaceuticals (RXRX) in Q3 2026, closing a stake of 35,484 shares — an estimated $130K sold.

Ascent Wealth Partners first reported a position in RXRX in Q2 2025 and held it in 5 quarters. The position peaked at $130K in Q2 2026. 277 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Ascent Wealth Partners reported no remaining Recursion Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Ascent Wealth Partners sold 35,484 Recursion Pharmaceuticals shares in Q3 2026, an estimated $130K.
  • Ascent Wealth Partners first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 5 quarters.
  • Ascent Wealth Partners's Recursion Pharmaceuticals position peaked at $130K in Q2 2026.
  • 277 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Ascent Wealth Partners's 13F filing for Q3 2026, filed 23 Oct 2026.